Deforolimus and succeed trial

To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Try the modernized ClinicalTrials. Learn more about the modernization effort. Hide glossary Glossary Study record managers: refer to the Data Element Definitions if submitting registration or results information.

Search for terms. Save this study. Warning You have reached the maximum number of saved studies Listing a study does not mean it has been evaluated by the U. Federal Government. Read our disclaimer for details. Last Update Posted : February 13, Study Description. The purpose of this study is to determine whether maintenance therapy with oral AP ridaforolimus , by preventing and controlling tumor growth for a prolonged period of time in patients with metastatic soft-tissue or bone sarcomas responding to chemotherapy, will result in clinically significant improvement in progression-free survival as compared to oral placebo.

Department of Health and Human Services. The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Breast Cancer Breast Neoplasms. Drug: ridaforolimus Drug: trastuzumab. Phase 2. Study Type :. Interventional Clinical Trial. Actual Enrollment :. Study Start Date :.

Actual Primary Completion Date :. Actual Study Completion Date :. Experimental: 1 10 mg oral tablets administered at 40 mg once daily for 5 consecutive days each week, followed by 2 days without ridaforolimus. Drug: ridaforolimus 10 mg oral tablets administered at 40 mg once daily for 5 consecutive days each week, followed by 2 days without ridaforolimus.

August 18, Key Record Dates. Data from the ACS estimates that about , new cases of lung cancer were diagnosed in the United States in and approximately , people will die from this disease. The vast majority of all lung cancers are the non-small cell type.

Prognosis for patients is primarily based on the time of diagnosis relative to the stage of the cancer. Treatment can consist of surgery, radiation, chemotherapy, and new therapies that target the tumor blood vessel growth. The mTOR protein acts as a "master switch" in cancer cells.

Blocking mTOR creates a starvation-like effect in cancer cells by interfering with cell growth, division, metabolism, and angiogenesis. Multiple Phase 1 and Phase 2 clinical trials of deforolimus in solid tumors and hematologic cancers have completed, or are in the process of patient enrollment. Food and Drug Administration.